Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vigabatrin - sanofi-aventis

Drug Profile

Vigabatrin - sanofi-aventis

Alternative Names: Gamma-vinyl-GABA; GVG; M071754; MDL 71754; RMI 71754; Sabril; Sabrilex; γ-vinyl-GABA

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Alfresa Pharma Corporation; Lundbeck Inc; National Institute on Drug Abuse; Sanofi; sanofi-aventis
  • Class Aminobutyric acids; Antiepileptic drugs; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Complex partial epilepsy; Epilepsy; Infantile spasms
  • Discontinued Cocaine abuse; Drug abuse

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Jun 2016 The US FDA approves the modified Risk Evaluation and Mitigation Strategy (REMS) for vigabatrin
  • 01 Sep 2015 Discontinued - Phase-I for Drug abuse (Methamphetamine abuse) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top